Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

2020417 citationsJournal Articlehybrid Open Access

Authors

Eric Van Cutsem · KU Leuven

Margaret A. Tempero · University of California San Francisco Medical Center

Darren Sigal · Scripps Clinic

Do‐Youn Oh · Seoul National University Hospital

Nicola Fazio · European Institute of Oncology

Teresa Macarulla · Vall d'Hebron Hospital Universitari

Erika Hitre

Abstract

The addition of PEGPH20 to AG increased the ORR but did not improve OS or PFS. The safety profile of PEGPH20 plus AG was consistent with that found in previous studies. These results do not support additional development of PEGPH20 in metastatic PDA.

Topics & Keywords

Pancreatic and Hepatic Oncology Research Neuroendocrine Tumor Research Advances Cholangiocarcinoma and Gallbladder Cancer Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 38, Issue 27, pp. 3185-3194

DOI: 10.1200/jco.20.00590

Field-Weighted Citation Impact: 21.51